Compound monographs — page 3
The Institute publishes a monograph for each of the 51 compounds in its assessment set. Each is one document in eight numbered parts with a per-indication evidence extract for every indication assessed.
Monographs
-
Semax is reported to increase expression of brain-derived neurotrophic factor and its receptor TrkB in rodent hippocampus, and to modulate monoaminergic transmission. Its approved Russian indications are ischaemic stroke and…
Low19 Apr 2026 -
Sermorelin stimulates pituitary growth-hormone release through the GHRH receptor. Its very short half-life confines the pharmacodynamic effect to a single secretory pulse, which is why its established clinical use was diagnostic…
Low15 Jun 2026 -
Elamipretide binds cardiolipin in the inner mitochondrial membrane, stabilising cristae curvature and the assembly of electron-transport-chain supercomplexes, and reducing cytochrome-c peroxidase activity. The result in…
Moderate17 Apr 2025 -
Glucagon receptor agonism increases hepatic fatty-acid oxidation, resting energy expenditure and hepatic lipid clearance; GLP-1 receptor agonism supplies appetite suppression and offsets the glycaemic consequences of glucagon…
Moderate19 Nov 2025 -
Thymosin beta-4 is an abundant intracellular actin-sequestering protein with reported extracellular activity in angiogenesis, cell migration and wound repair. TB-500 comprises the actin-binding motif and is supplied on the…
Very low13 Oct 2025 -
GLP-2 receptor agonism promotes intestinal mucosal growth, increases villus height and crypt depth, slows gastric emptying and reduces intestinal secretion. The therapeutic consequence in short-bowel syndrome is improved fluid…
Moderate30 Jan 2024 -
Tesamorelin stimulates the pituitary to release endogenous growth hormone in a pulsatile pattern, preserving the physiological feedback architecture that exogenous growth hormone bypasses. Downstream IGF-1 elevation drives…
Moderate01 Sep 2024 -
Thymalin is a fractionated calf-thymus extract registered in the Russian Federation as an immunomodulator. Because its composition is not defined, no mechanism can be stated at molecular level, and batch-to-batch consistency is…
Very low15 Jul 2026 -
Thymosin alpha-1 promotes T-lymphocyte differentiation and maturation, increases interleukin-2 and interferon-gamma production, and enhances dendritic-cell function. Its clinical applications exploit immune reconstitution rather…
Moderate23 Jan 2026 -
Thymosin beta-4 sequesters monomeric actin and thereby regulates cytoskeletal dynamics, cell migration and wound repair. Extracellular administration in preclinical models promotes angiogenesis, keratinocyte and endothelial…
Low13 Dec 2023 -
Tirzepatide engages both incretin receptors from a single molecule. GLP-1 receptor agonism reproduces the insulinotropic, glucagonostatic, gastric and central appetite effects of the selective class. Concurrent GIP receptor…
High16 Jan 2025
page 3 of 3